Our Sept. news includes a possible clinical marker and therapy target in Alzheimer disease and MS findings from an optical coherence tomography study.
European Committee for Treatment and Research in Multiple Sclerosis Congress (ECTRIMS)
This ECTRIMS session includes studies using 7T and 3T MRI images and translocator protein PET scans, as well as phenotypes in gray matter and more.
Advertisement
Research presented at this ECTRIMS session covered management of multiple sclerosis-related fatigue, cognitive issues, and gait impairment.
Hot Topics session at ECTRIMS 2016: treat early active RRMS with potent induction therapy or immunomodulation then escalation? Where do you stand?
The session featured a study comparing MRI criteria for diagnosing MS, the role of spinal cord volume loss in predicting disease activity, and more.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
CTAD Presentation Lays Insights Into Disappointing Phase 3 EVOKE Trial of GLP-1 Semaglutide in Alzheimer Disease
2
Additional Insights From the U.S. POINTER Study at CTAD 2025: Heather M. Snyder, PhD
3
New Clarity AD Analysis Reveal How Lecanemab Engages and Clears Neurotoxic Protofibrils in Alzheimer Disease
4
Merck’s Novel Antibody MK-2214 Receives FDA Fast-Track Designation Following Phase 1 Results
5
